Polydrug dependence and psychiatric comorbidity among heroin injectors

doi:10.1016/S0376-8716(97)00117-8

Drug and Alcohol Dependence

Volume 48, Issue 2, 25 November 1997, Pages 135-141

https://doi.org/10.1016/S0376-8716(97)00117-8 Get rights and content

Abstract

The prevalence of diagnoses of substance dependence, anxiety disorders and depressive disorders were estimated in a sample of 222 heroin injectors, using the Composite International Diagnostic Interview. Subjects had a median of three lifetime substance diagnoses and two current diagnoses. A total of 60% met the criteria for a lifetime anxiety disorder, and 51% had a current anxiety disorder. A depressive disorder was diagnosed in 41% of subjects, with 30% having a current diagnosis. There were significant positive correlations between the number of lifetime drug dependence diagnoses and the number of lifetime anxiety and affective disorders (r = 0.41), and the number of current drug dependence diagnoses and the number of current comorbid diagnoses (r = 0.32). After controlling for other variables, the only significant independent predictor of the number of lifetime and current dependence diagnoses was the number of comorbid diagnoses.

References (19)

S. Darke et al.
Levels and correlates of polydrug use among heroin users and regular amphetamine users
Drug Alcohol Depend.
(1995)
S.H. Dinwiddie et al.
Psychopathology and HIV risk behaviours among injection drug users in and out of treatment
Drug Alcohol Depend.
(1996)
W. Hall et al.
Crime and drug use among applicants for methadone maintenance
Drug Alcohol Depend.
(1993)
J.V. Limbeek et al.
Prevalence of psychopathology among drug-addicted Dutch
J. Subst. Abuse Treat.
(1992)
S.S. Luthar et al.
Gender differences among opioid users: pathways to disorder and profiles of psychopathology
Drug Alcohol Depend.
(1996)
E. Corty et al.
Psychological symptoms in methadone maintenance patients: prevalence and change over treatment
J. Consult. Clin. Psychol.
(1988)
S. Darke et al.
Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose
Addiction
(1996)
S. Darke et al.
Fatal heroin overdose: a review
Addiction
(1996)
M. Gossop et al.
The Severity of Dependence Scale (SDS) in English and Australian samples of heroin, cocaine and amphetamine users
Addiction
(1995)

There are more references available in the full text version of this article.

Cited by (169)

Measuring the importance of different barriers to opioid agonist treatment using best-worst scaling in an Australian setting
2023, Health Policy
Opioid agonist treatment (OAT) is an effective treatment for opioid use disorder (OUD), however several client barriers to OAT are reported. Client importance of these barriers using economic preference elicitation measures have not been identified. This paper determines the most important OAT barriers using best-worst scaling (BWS) and compares the results of BWS to Likert scale.
Cross-sectional self-completed survey with 191 opioid dependent clients who attended Australian needle and syringe sites. Participants were presented 15 Likert scale barriers and 15 BWS barrier scenarios. The BWS data was presented using count analysis, multinomial logit and mixed logit models. The ranking of barrier items was completed using three BWS methods and one Likert scale method, with share preference results (BWS) or mean scores (Likert) used to rank the 15 barriers.
The most important client barriers were ‘enjoy using opioids’, ‘lack of support services’ and ‘hard to access’. The four ranking methods produced different barrier rankings for the most important barriers, but similar results for the least important barriers.
Policies around OAT as a harm reduction approach, increased support services and increased availability of OAT services would be beneficial in improving OAT uptake. Comparing BWS and Likert methods produced different highest ranked barriers, indicating the method used to identify preferences has significant implications on the type of intervention prioritised.
The phenomics and genetics of addictive and affective comorbidity in opioid use disorder
2021, Drug and Alcohol Dependence
Opioid use disorder (OUD) creates significant public health and economic burdens worldwide. Therefore, understanding the risk factors that lead to the development of OUD is fundamental to reducing both its prevalence and its impact. Significant sources of OUD risk include co-occurring lifetime and current diagnoses of both psychiatric disorders, primarily mood disorders, and other substance use disorders, and unique and shared genetic factors. Although there appears to be pleiotropy between OUD and both mood and substance use disorders, this aspect of OUD risk is poorly understood. In this review, we describe the prevalence and clinical significance of addictive and affective comorbidities as risk factors for OUD development as a basis for rational opioid prescribing and OUD treatment and to improve efforts to prevent the disorder. We also review the genetic variants that have been associated with OUD and other addictive and affective disorders to highlight targets for future study and risk assessment protocols.
Association of opioid misuse with anxiety and depression: A systematic review of the literature
2021, Clinical Psychology Review
Citation Excerpt :
Although few of these studies included a non-opioid-using control group, population prevalence estimates were compared to those of the general population. Of the studies reviewed, six examined prevalence among individuals who use opioids (Brooner, King, Kidorf, Schmidt, & Bigelow, 1997; Darke et al., 1994; Darke & Ross, 1997; Kosten & Rounsaville, 1986; Kosten, Rounsaville, & Kleber, 1985; Maddux, Desmond, & Costello, 1987). Although assessment methodology (i.e., self-report vs. clinical interview) varied across studies, each indicated elevated (compared to the general population estimates) rates of anxiety and depressive disorders among opioid users.
The opioid epidemic is a public health problem associated with a host of negative outcomes. Although clinicians recognize covariation between opioid misuse with anxiety and depressive symptoms and disorders, research on this topic has only recently accumulated. Progress in this domain is impeded by the lack of systematic and integrative research to better understand and treat these co-occurring problems. This paper represents the first attempt to systematically review the empirical literature examining relations between opioid use and misuse, and anxiety and depression. In the first section, we define key terms and describe the article selection strategy. In the second section, we review the prevalence of anxiety and depressive symptoms among individuals who use and misuse prescription and illicit opioids. In the third section, we review the magnitude of associations between anxiety and depressive symptoms and disorders with opioid misuse, as well as highlight studies examining the longitudinal and temporal sequence of the relations between these variables. In the fourth section, we focus on experimental therapeutics, reviewing what is known about individual difference and transdiagnostic vulnerability factors for anxiety and depression that might contribute to opioid misuse and its symptoms. Finally, we discuss current knowledge gaps and present a heuristic model to guide future research.
Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients
2019, Addictive Behaviors
A mainstay treatment for opioid addiction in North America is methadone maintenance therapy (MMT) – a form of opiate agonist therapy (OAT). While efficacious for treating opioid addiction, MMT fails to address the concurrent polysubstance use that is common among opioid dependent clients. Moreover, psychosocial approaches for addressing polysubstance use during MMT are lacking. Our study's goals were to validate the use of the four-factor personality model of substance use vulnerability in MMT clients, and to demonstrate theoretically-relevant relationships of personality to concurrent substance use while receiving MMT.
Respondents included 138 daily-witnessed MMT clients (65.9% male, 79.7% Caucasian), mean age (SD) 40.18 (11.56), recruited across four Canadian MMT clinics. Bayesian confirmatory factor analysis was used to establish the structural validity of the four-factor personality model of substance use vulnerability (operationalized with the Substance Use Risk Profile Scale [SURPS]) in MMT clients. SURPS personality scores were then used as predictors for specific forms of recent (past 30-day) substance use.
Using a latent hierarchal model, hopelessness was associated with recent opioid use; anxiety sensitivity with recent tranquilizer use; and sensation seeking with recent alcohol, cannabis, and stimulant use.
Personality is associated with substance use patterns and may be an appropriate target for intervention for those undergoing MMT to reduce opioid use, and potentially dangerous concurrent use of other drugs, while receiving methadone.
Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada
2019, Addictive Behaviors
High-risk injection behaviors are associated with high prevalence of mental health problems among people who inject drugs (PWID). However, whether the use of mental health services is associated with lower risk of sharing injection material remains undetermined. This study aims to examine the association between mental health service utilisation and receptive sharing risk, and determine the potential modifying effect of psychological distress on this association.
Participants answered an interviewer-administered questionnaire at 3-month intervals gathering information on sociodemographic characteristics, substance use and related behaviors, services utilisation and significant mental health markers. Relationship between the use of mental health services and receptive sharing was modeled using the generalized estimating equation (GEE), controlling for age at baseline, gender, and other potential confounders. Psychological distress was estimated using the Kessler Psychological Distress Scale (K10). Effect modification was investigated by adding an interaction term in the univariate GEE analysis.
358 participants contributed to 2537 visits (median age 40.3, 82% male). Mental health service utilisation was reported in 631 visits (25%), receptive sharing in 321 visits (13%) and severe psychological distress in 359 visits (14%). In multivariate GEE analyses, a significant association was identified between receptive sharing and the use of mental health services (aOR = 0.69; 95% CI = 0.50–0.94). We found no evidence of effect modification by psychological distress.
Among PWID, mental health service utilisation was associated with lower likelihood of receptive sharing, regardless of level of psychological distress. These findings should be taken into account when designing harm reduction strategies for this population.
Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey
2019, Journal of Substance Abuse Treatment
Past research shows that among individuals with substance use disorders, the presence of a co-occurring mental illness can influence the initiation, course, and success of behavioral health treatment, but little research has examined people with opioid use disorder (OUD) specifically.
Using the 2008–2014 National Survey on Drug Use and Health, this study examines the utilization of substance use disorder and mental health treatment among individuals with OUD and different degrees of mental illness severity. The study also examined types of treatment, perceived unmet need for treatment, and barriers to care.
47% of individuals with OUD and co-occurring mild/moderate mental illness did not receive any behavioral health treatment, and 21% of those with co-occurring serious mental illnesses did not receive any behavioral health treatment. Among those with OUD and co-occurring mild/moderate mental illness, 16% reported receiving both substance use disorder and mental health treatment; among those with co-occurring serious mental illness the rate was 32%. The most common form of treatment was prescription medication for mental health, and this was true regardless of whether or not the individual had any mental illness. More than 50% of the study population reported financial difficulties as a barrier to treatment.
A high proportion of individuals with OUD and co-occurring mental illness are not receiving needed care. However, nearly one in five of those with OUD but no diagnosed mental illness is receiving prescription medication for mental illness. These findings suggest that there is a need to better facilitate access to and coordinate behavioral health care across settings for individuals with OUD.

View all citing articles on Scopus

View full text

Polydrug dependence and psychiatric comorbidity among heroin injectors

Abstract

Drug Alcohol Depend.

Drug Alcohol Depend.

Drug Alcohol Depend.

J. Subst. Abuse Treat.

Drug Alcohol Depend.

Psychological symptoms in methadone maintenance patients: prevalence and change over treatment

J. Consult. Clin. Psychol.

Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose

Addiction

Fatal heroin overdose: a review

Addiction

The Severity of Dependence Scale (SDS) in English and Australian samples of heroin, cocaine and amphetamine users

Addiction